| Tigecycline: in community-acquired pneumonia. | |
| | |
MedLine Citation:
|
PMID: 19093704 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Tigecycline is a first-in-class glycylcycline, broad-spectrum, intravenous antibacterial developed to overcome the two major mechanisms of tetracycline resistance (ribosomal protection and efflux). The drug has been in use since 2005 for complicated intra-abdominal infections, and complicated skin and soft tissue structure infections, but is currently being assessed in the US for community-acquired pneumonia (CAP) in adults. In vitro, tigecycline had good activity against a range of Gram-positive, Gram-negative and atypical community-acquired respiratory tract pathogens implicated in CAP. Compared with other antibacterials, tigecycline has a prolonged post-antibiotic effect against key bacteria and a long serum elimination half-life in humans. The drug effectively penetrates lung tissue. The combined results of two well designed, phase III studies demonstrated that tigecycline 100 mg initially, followed by 50 mg every 12 hours for 7-14 days was not inferior to recommended dosages of levofloxacin in the treatment of hospitalized patients with CAP. Clinical cure rates were 89.7% versus 86.3% in the clinically evaluable population and 81.0% versus 79.7% in the clinical modified intent-to-treat population. Tigecycline was generally well tolerated in patients with CAP. |
| | |
Authors:
|
Kate McKeage; Gillian M Keating |
Related Documents
:
|
11566974 - Activity of the ketolide antibacterial telithromycin against typical community-acquired... 10862304 - Pneumocystis carnii pneumonia in aids--an autopsy report. 15889364 - Antiseptic "resistance": real or perceived threat? 3850124 - Breaking the race barrier. 18265774 - The ageing uk population--considerations for the restorative dentist. 1452764 - Depression, problem-solving ability, and problem-solving appraisals. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs Volume: 68 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-12-19 Completed Date: 2009-03-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 2633-44 Citation Subset: IM |
Affiliation:
|
Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Bacterial Agents
/
chemistry,
pharmacokinetics,
therapeutic use* Area Under Curve Clinical Trials, Phase III as Topic Community-Acquired Infections / drug therapy*, microbiology Half-Life Humans Injections, Intravenous Minocycline / analogs & derivatives*, chemistry, pharmacokinetics, therapeutic use Pneumonia, Bacterial / drug therapy*, microbiology |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/tigecycline; 10118-90-8/Minocycline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antidepressants for the treatment of chronic pain.
Next Document: Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.